Global Consumer Perspectives on Longevity

New Personalized Longevity Supplementation From Saints One  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ February 14th, 2024 | [Read Online]( Saints One is your longevity 360° Personalized daily supplementation, DNA Age Testing, 24/7 AI via the Saints One app, and your own longevity concierge – all in one plan. Good Morning , In today's edition of Longr Reads, we embark on an analytical exploration of the recent technological breakthroughs that are poised to redefine the landscape of longevity healthcare. As the global demographic tilts increasingly towards an older population, the implications for healthcare systems, economies, and individual well-being are profound and multifaceted. This shift is not merely a challenge to be managed but a wellspring of opportunity for innovation, investment, and improvement in the quality of life for older adults. The narrative of aging is being rewritten by advances in biotechnology, digital health, and personalized medicine, marking a significant departure from traditional reactive care models towards proactive, preventive, and personalized healthcare strategies. This issue delves into the intersection of technology and healthcare, analyzing how innovations are extending healthspan — the period of life spent in good health — and lifespan. We consider the broader economic, social, and individual implications of these developments, highlighting how they contribute to a more resilient, inclusive, and healthy society. From investment trends spurred by demographic shifts to groundbreaking apps democratizing cardiovascular care, and the visionary efforts to tackle aging at its core, each article presents a facet of the complex mosaic of longevity healthcare. As we navigate through these transformative developments, our analysis is rooted in a critical understanding of their potential to not just extend life but to enhance its quality. The integration of cutting-edge technology and healthcare, underscored by a commitment to accessibility and personalized care, heralds a new era where aging is not an inexorable decline but a challenge that can be met with innovation and insight. Let’s dive in … EVERY WEDNESDAY Research Round-up Ezra raises $21M to detect Cancer in Minutes Ezra's recent fundraising achievement of $21 million, elevating its total investment to $41 million, represents a significant milestone in the fight against cancer through early detection. Co-led by Healthier Capital and FirstMark Capital, this round of funding underscores the growing recognition of Ezra's revolutionary Full Body Scan technology, which aims to make early cancer detection more accessible and efficient. With the backing of notable figures such as Amir Dan Rubin, former CEO of Amazon’s One Medical, and the former Chairman of the NHS, Lord David Prior, Ezra's expansion plans and continued development of AI-driven MRI scans signal a transformative shift towards preventative healthcare models. Ezra's approach reflects a strategic pivot in healthcare investment, focusing on technologies that promise not only to enhance diagnostic accuracy but also to democratize access to advanced screening methods. The company's goal to accelerate its expansion across North America and enhance the affordability of full-body MRI scans through AI is a testament to the potential impact of integrating technology and healthcare. This investment is a clear indication of the confidence in Ezra's vision to improve survival rates by catching cancer and other diseases at their nascent stages, emphasizing the critical role of early detection in changing the dynamics of healthcare outcomes. Read the [full article here](. The most striking discovery was in the elderly, where taurine levels were a staggering 80% lower than in their younger counterparts. This nutrient's potential seems promising, especially when considering its ability to add an estimated seven to eight years to human life. Hevolution Announces 49 awards in $115m Longevity Grants Program The Hevolution Foundation's announcement of 49 awards totaling $115 million under its HF-GRO program marks a watershed moment in aging research funding. This initiative is poised to catalyze significant advancements in understanding the biological underpinnings of aging, emphasizing a shift from treating age-associated diseases to unraveling the root causes of aging itself. By targeting the foundational mechanisms behind biological aging, Hevolution is spearheading a strategic approach to extend healthspan, reflecting a deep commitment to transforming the landscape of healthy aging. This funding initiative is indicative of a broader strategic vision that seeks to bridge significant gaps in aging research. By investing in a diverse array of pre-clinical studies, Hevolution is not just providing capital but is also fostering an ecosystem of innovation aimed at unlocking the mysteries of longevity. The decision to fund projects across a global network of institutions underscores the foundation's ambition to lead a concerted, international effort in aging research. This approach serves as a blueprint for future investments in the field, highlighting the necessity of a concerted global effort to tackle one of the most pressing challenges of our time – aging. Read the [full article here](. Epidemiological observations have long hinted at a curious phenomenon: populations residing at high altitudes often live longer and seem less susceptible to certain diseases. This study sought to replicate these findings in a controlled animal setting, shedding light on the potential benefits of high-altitude living. GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D BioAge Labs' securing of $170 million in Series D funding, led by Sofinnova, catapults the company into a vanguard position within the longevity research sphere. This significant financial injection is earmarked for advancing BioAge Labs' innovative pipeline focused on targeting the mechanisms of aging, with a particular emphasis on metabolic disease. The collaboration with Eli Lilly and the development of a combo candidate that might enhance weight loss without muscle loss exemplify the strategic alignment of BioAge Labs' research focus with the burgeoning interest in GLP-1s. This funding not only underscores the financial community's confidence in BioAge Labs' strategic direction but also highlights the evolving landscape of longevity research, where the focus is shifting towards interventions that address the biological processes of aging. The involvement of major institutional biotech investors and the venture arms of pharmaceutical giants like Eli Lilly and Amgen reflect a broader industry trend towards prioritizing longevity and metabolic diseases. BioAge Labs' approach, leveraging cutting-edge science to develop therapies aimed at improving healthspan, epitomizes the strategic investment ethos required to drive forward the field of longevity science. Read the [full article here](. Sima, the last surviving rat from the study, stands as a testament to the treatment's potential. She has already surpassed the typical lifespan for her species, drawing parallels to a human living beyond 126 years. Today's edition of Longr Reads delves into the strategic underpinnings of significant financial movements within the longevity healthcare sector, illuminating a concerted effort to redefine our approach to aging and healthcare innovation. The narratives of Ezra, Hevolution Foundation, and BioAge Labs, each securing substantial funding for their pioneering projects, underscore a pivotal shift towards prioritizing early detection, understanding the fundamental processes of aging, and targeting metabolic diseases with novel therapies. The strategic investments in Ezra's AI-driven cancer detection technology, Hevolution's ambitious grants program for aging research, and BioAge Labs' focus on metabolic disease interventions reflect a broader industry trend towards integrating technology and science to preemptively combat the effects of aging. These developments signal a growing recognition of the potential to not only extend life but also to enhance the quality of life, emphasizing prevention over treatment and systemic understanding over symptomatic relief. As we witness these entities navigate the complexities of aging research and healthcare innovation, it becomes increasingly clear that the future of longevity lies in a multidisciplinary approach. By marrying financial acumen with scientific rigor, the sector is setting the stage for breakthroughs that promise to transform our understanding and management of aging. The insights garnered from today's discussions offer a glimpse into a future where aging is not feared but managed through proactive and preventive measures, ensuring healthier, longer lives for the global population. Until next time, The Longr Reads Team "Innovation is the ability to see change as an opportunity - not a threat." Steve Jobs Longr Reads' of the Week - Longevity: Can Aging be Reversed? ([The Economist - Youtube]( - Investing in Longevity 101 ([Longevity Technology - Youtube]( - The Global Roadmap for Healthy Longevity Initiative ([National Academies]( THE LONGEVITY INVESTOR REPORT This exclusive first edition has a complete sector breakdown, and an introduction to some of the key things professional longevity investors are looking at. [FREE DOWNLOAD]( [FREE LONGEVITY INVESTOR REPORT! CLICK HERE!!]( Longr is building access to longevity across: generative AI, therapeutics, wellness products, clinics, research, community, and marketplaces. Transforming visionary concepts into tangible solutions - we are facilitating widespread adoption of longevity-enhancing products and platforms. [Advertise with us](mailto:partnerships@longr.io) // [Book a call with Longr](mailto:ir@longr.io) 107 North Orange Street, Wilmington, Delaware 19801, United States You received this email from Longr Reads. If you would like to unsubscribe, [click here](.